Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02062073 · ClinicalTrials.gov registry record · Phase 1

Dermal Safety Study to Evaluate the Sensitizing Potential of Abametapir Lotion

A Phase 1 study, sponsored by Dr. Reddy's Laboratories Limited.

Completed
Registry status
Phase 1
Development phase
238
Enrollment target

NCT02062073 is a Phase 1 study that has completed, run by Dr. Reddy's Laboratories Limited. The registered enrollment target is 238 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02062073, a Phase 1 study, has completed, sponsored by Dr. Reddy's Laboratories Limited.

COMPLETED
Registry status
Phase 1
Development phase
238 participants
Enrollment target

Study Summary

Purpose of this study will be to determine the potential of abametapir lotion to induce sensitization by repeated topical application to the healthy skin of humans under controlled conditions.

Interventions

  • DRUG Abametapir Lotion 0.74% w/w
  • OTHER 0.1% sodium lauryl sulfate
  • OTHER saline 0.9%
  • OTHER Vehicle Lotion

Trial Details

FieldValue
Enrollment Target 238 participants
Start Date 2014-01
Est. Completion 2014-06
Phase Phase 1

Sponsor

Dr. Reddy's Laboratories Limited

52 total trials

What the Registry Record Tells You About NCT02062073

The ClinicalTrials.gov registry entry for NCT02062073 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 238 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dr. Reddy's Laboratories Limited, which has 52 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 4 interventions - of which Abametapir Lotion 0.74% w/w is the first listed.

NCT02062073 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT02062073 about?

NCT02062073 is a clinical study titled "Dermal Safety Study to Evaluate the Sensitizing Potential of Abametapir Lotion". Purpose of this study will be to determine the potential of abametapir lotion to induce sensitization by repeated topical application to the healthy skin of humans under controlled conditions.

What is the current status of trial NCT02062073?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 238 participants. The study started on 2014-01. Estimated completion is 2014-06.

What interventions are being tested in trial NCT02062073?

The interventions under investigation include: Abametapir Lotion 0.74% w/w (DRUG), 0.1% sodium lauryl sulfate (OTHER), saline 0.9% (OTHER), Vehicle Lotion (OTHER).

Who is sponsoring clinical trial NCT02062073?

This trial is sponsored by Dr. Reddy's Laboratories Limited, which has 52 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.